PURE Bioscience's Treatment For Swine Flu Meets CDC Standards
April 27, 2009 at 14:16 PM EDT
PURE Bioscience (Nasdaq: PURE) announced that its PureGreen24 antimicrobial treatment meets CDC recommendations for treating patients with swine flu. The stock price surged 99 cents to $2.84.
